CN111867578A - 包含帕马考昔及普瑞巴林的用于治疗疼痛的药剂学组合物 - Google Patents
包含帕马考昔及普瑞巴林的用于治疗疼痛的药剂学组合物 Download PDFInfo
- Publication number
- CN111867578A CN111867578A CN201980020180.0A CN201980020180A CN111867578A CN 111867578 A CN111867578 A CN 111867578A CN 201980020180 A CN201980020180 A CN 201980020180A CN 111867578 A CN111867578 A CN 111867578A
- Authority
- CN
- China
- Prior art keywords
- pregabalin
- pharmaceutical composition
- pain
- composition
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 title claims abstract description 86
- 229960001233 pregabalin Drugs 0.000 title claims abstract description 86
- 208000002193 Pain Diseases 0.000 title claims abstract description 44
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 30
- 208000004296 neuralgia Diseases 0.000 claims abstract description 9
- 208000000094 Chronic Pain Diseases 0.000 claims abstract description 6
- 206010061218 Inflammation Diseases 0.000 claims abstract description 6
- 230000004054 inflammatory process Effects 0.000 claims abstract description 6
- 208000005298 acute pain Diseases 0.000 claims abstract description 5
- 230000001154 acute effect Effects 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 63
- 239000003826 tablet Substances 0.000 claims description 60
- 239000002775 capsule Substances 0.000 claims description 25
- 238000013268 sustained release Methods 0.000 claims description 20
- 239000012730 sustained-release form Substances 0.000 claims description 20
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 10
- 238000000576 coating method Methods 0.000 claims description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 9
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 8
- 208000004454 Hyperalgesia Diseases 0.000 claims description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 8
- 229920002125 Sokalan® Polymers 0.000 claims description 8
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 229960001631 carbomer Drugs 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010413 sodium alginate Nutrition 0.000 claims description 7
- 239000000661 sodium alginate Substances 0.000 claims description 7
- 229940005550 sodium alginate Drugs 0.000 claims description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 208000001640 Fibromyalgia Diseases 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 5
- 239000001856 Ethyl cellulose Substances 0.000 claims description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 5
- 208000035154 Hyperesthesia Diseases 0.000 claims description 5
- 206010034464 Periarthritis Diseases 0.000 claims description 5
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 5
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 5
- 229920001249 ethyl cellulose Polymers 0.000 claims description 5
- 201000010603 frozen shoulder Diseases 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 208000008035 Back Pain Diseases 0.000 claims description 4
- 206010058019 Cancer Pain Diseases 0.000 claims description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
- 208000008930 Low Back Pain Diseases 0.000 claims description 4
- 208000008765 Sciatica Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 201000002661 Spondylitis Diseases 0.000 claims description 2
- 229940057948 magnesium stearate Drugs 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 1
- 230000008058 pain sensation Effects 0.000 claims 1
- 229960001407 sodium bicarbonate Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 10
- 150000001875 compounds Chemical class 0.000 abstract description 8
- 239000004480 active ingredient Substances 0.000 abstract description 6
- 208000021722 neuropathic pain Diseases 0.000 abstract description 6
- 239000008177 pharmaceutical agent Substances 0.000 abstract description 3
- 230000000202 analgesic effect Effects 0.000 abstract 3
- 230000001684 chronic effect Effects 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 description 32
- 230000000052 comparative effect Effects 0.000 description 27
- 239000003814 drug Substances 0.000 description 26
- 238000007922 dissolution test Methods 0.000 description 25
- 229940079593 drug Drugs 0.000 description 23
- 239000002552 dosage form Substances 0.000 description 18
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 12
- IJWPAFMIFNSIGD-UHFFFAOYSA-N 4-[3-(3-fluorophenyl)-5,5-dimethyl-4-oxofuran-2-yl]benzenesulfonamide Chemical compound O=C1C(C)(C)OC(C=2C=CC(=CC=2)S(N)(=O)=O)=C1C1=CC=CC(F)=C1 IJWPAFMIFNSIGD-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 229950006009 polmacoxib Drugs 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000007906 compression Methods 0.000 description 7
- 230000006835 compression Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000010998 test method Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 235000019589 hardness Nutrition 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000012085 test solution Substances 0.000 description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 4
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000002981 neuropathic effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 150000008575 L-amino acids Chemical class 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010053552 allodynia Diseases 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 230000005176 gastrointestinal motility Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 239000007974 sodium acetate buffer Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000007939 sustained release tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- ZJMWDULLCAJDLQ-VGMFFHCQSA-N (3s)-3-(aminomethyl)-5-methylhexanoic acid Chemical compound CC(C)C[C@H](CN)CC(O)=O.CC(C)C[C@H](CN)CC(O)=O ZJMWDULLCAJDLQ-VGMFFHCQSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010061591 Borrelia infection Diseases 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical class CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 208000020764 Sensation disease Diseases 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007642 Vitamin B Deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003282 amino acid receptor affecting agent Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000002342 diabetic polyneuropathy Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000036734 inhibitory postsynaptic potential Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- ZLEFBGVPYZUUGI-UHFFFAOYSA-N methyl benzoate;2-methylbenzoic acid Chemical compound COC(=O)C1=CC=CC=C1.CC1=CC=CC=C1C(O)=O ZLEFBGVPYZUUGI-UHFFFAOYSA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000007433 nerve pathway Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004584 polyacrylic acid Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- VYOXRXJKMLDPLA-UHFFFAOYSA-N propyl benzoate;2-propylbenzoic acid Chemical compound CCCOC(=O)C1=CC=CC=C1.CCCC1=CC=CC=C1C(O)=O VYOXRXJKMLDPLA-UHFFFAOYSA-N 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及包含帕马考昔及普瑞巴林的复合制剂。本发明涉及帕马考昔及普瑞巴林两种活性成分的药学组合物及药剂或镇痛剂,更具体而言,涉及作为用于治疗因炎症性及多种因素引起的中度急性、慢性或神经病性疼痛的药剂或镇痛剂的效果及用途。
Description
技术领域
本发明涉及包含帕马考昔(polmacoxib)和普瑞巴林(pregabalin)的组合物,更详细而言,涉及一种包含帕马考昔和普瑞巴林的用于治疗疼痛的药剂学组合物,其中,所述帕马考昔可以有用地用作稳定性优秀并以低含量便表现出优秀效果的非甾体抗炎剂,所述普瑞巴林为广谱抗惊厥剂,用于神经病理学疼痛治疗。
背景技术
疼痛定义为与实际的或潜在性的组织损伤相关联的或描述为这种损伤的不愉快的感觉或感情性体验。也指通过由痛觉感受器与神经纤维构成的神经通路来刺激与大脑皮质和边缘系统区域相接的部位而引起的痛觉及感觉障碍。其作为用于保护身体的防御手段,可以说是在身体内部或外部传递异常的警告反应。疼痛本身并非疾病,因而即使消除疼痛,也并非治愈成因疾病。
原因大致可以分为因躯体组织或内脏组织的损伤或炎症引起的知觉性疼痛、神经损伤后发生的神经病性疼痛。知觉性疼痛可以例如皮肤痛、内脏痛、躯体痛、知觉性神经痛、神经根相关痛、躯体相关痛等,神经病性疼痛有因末梢神经或中枢神经功能异常导致的疼痛。在疼痛长期持续或其刺激过于强烈的情况下,则会干扰日常生活,甚至导致焦虑和恐惧。因此,患有慢性疼痛的人往往患有抑郁症,因而在治疗时也需考虑这种特性。
普瑞巴林的化合物名称为(S)-(+)-3-(氨基甲基)-5-甲基-己酸((S)-(+)-3-(aminomethyl)-5-methyl-hexanoic acid),具有下述化学式1的结构。
[化学式1]
已知普瑞巴林结合于钙通道的阿尔法-2-德尔塔(α2δ)亚基(subunit),因而神经细胞末端的钙离子流入减少,包含谷氨酸(glutamate)和去甲肾上腺素(noradrenalin)的多种兴奋性神经递质的分泌减少,从而使神经细胞的功能恢复到正常水平。普瑞巴林作为与脑神经元活性的调节相关的内源性神经递质,是与神经处理相关的γ-氨基丁酸(γ-amino butyric acid,G ABA)的类似物。
已阐明普瑞巴林激活L-谷氨酸脱羧酶(L-glutamate decarboxylase,GA D),对癫痫发作具有剂量依赖性保护效果,是中枢神经系统(central nerv ous system,CNS)活性化合物。另外,普瑞巴林因激活GAD而可以在抗惊厥疗法中有用地使用,这是因为,其作为释放到30%脑突触(synapse)的大脑主要抑制神经递质之一的γ-氨基丁酸(gamma-aminobutyric acid,G ABA)的氨基酸神经递质,引起抑制性突触后电位。
这种普瑞巴林药物可以用于治疗癫痫、神经病理学疼痛(neuropatholo gicalpain)、广泛性焦虑障碍(generalized anxiety discorders)、纤维肌痛等。
其中,作为可能诱发神经病理学疼痛的原因,有糖尿病多发性神经障碍、带状疱疹后神经痛、肿瘤、化学疗法、三叉神经痛、酗酒、维生素B缺乏症、幻觉痛、疏螺旋体感染、复合部位疼痛综合症、腕管综合症、腰痛及后天性免疫缺陷症等。
普瑞巴林药物为呈白色或浅黄色的结晶性粉末,具有易溶于水的特性。该药物在体内表现出快速高效吸收,约1.3小时出现最大血液浓度,生物利用率约90%。另外,大部分通过肾脏从尿道排出,半衰期约5至6.5小时。普瑞巴林借助于L-氨基酸转运系统而吸收,因而在胃肠道中吸收不均一,在L-氨基酸转运载体(L-amino acid transporter)密集的小肠上部吸收最多,因而平均吸收时段为6小时以下。由于这种理由,现在许多制药公司摆脱生产率低下的胶囊型,正在开发诸如普瑞巴林缓释片、胃滞留片剂等的片剂剂型。
帕马考昔是现在以Acelex品名销售的药物,其结构如下述化学式2所示。
[化学式2]
本发明的药学组合物所使用的有效成分帕马考昔的化合物名称为5-(4-(氨基磺酰基)苯基)-2,2-二甲基-4-(3-氟苯基)-3(2H)-呋喃酮。作为COX-2的选择性抑制剂,与普通NSAIDs相比,其胃肠道毒性低,已知对炎症性疾病、炎症相关疾病、疼痛、实体癌、血管新生相关疾病、阿尔茨海默氏症、癫痫发作及惊厥、中风、癫痫等有效(韩国授权专利第10-0495389号)。
COX-2(环氧化酶)负责前列腺素(prostaglandin)的生成。已确认C OX-1及COX-2两种异构体(isoform),并显示出COX-2由促炎症刺激而诱发,是被认为在疼痛、炎症及发热相关的前列腺素(prostanoid)调节子的合成中发挥主要作用的酶的异构体。
试图通过组合作为发挥这种作用的COX-2抑制剂的帕马考昔与普瑞巴林来治疗疼痛。
申请的焦点在于,涉及一种帕马考昔与普瑞巴林的组合可以对重度至中度疼痛,特别是存在炎症性要素的疼痛获得附加性效果的药学组合物,对其组合进行验证。
发明内容
发明要解决的问题
本发明人希望为了进一步增进帕马考昔(polmacoxib)与普瑞巴林(pregabalin)组合对疼痛的协同效应及相比原有制品的药物服用便利性,将互不相同的两种活性成分制成单一剂型。
用于解决问题的手段
本发明提供一种包含帕马考昔及普瑞巴林的用于治疗疼痛的药剂学组合物。
根据一个实施例,所述组合物可以用于治疗因炎症性或神经病症性诱发的急性或慢性疼痛。具体而言,可以将包括糖尿病性神经障碍的神经源性疼痛(neurogenic pain)、因广泛性焦虑障碍(generalized anxiety disorder)导致的疼痛、纤维肌痛(fibromyalgia)、痛觉过敏症(hyperalgesia)、异常痛觉(allodynia)、癌症疼痛(cancerpain)、骨关节炎(osteoarthritis)、类风湿性关节炎(rheumatoid arthritis)、脊椎炎(spondylitis)、五十肩(frozen shoulder)、腰痛(lumbodynia)或坐骨神经痛(sciatica)作为适应症。
根据一个实施例,帕马考昔相对普瑞巴林的比率可以为1:1至1:600重量比。
另外,帕马考昔相对普瑞巴林的比率可以为1:1至300:1重量比,可以具有2:1至2:300重量比。
根据一个实施例,相对于组合物总重量,可以包含帕马考昔0.1至10重量%及普瑞巴林10至50重量%。
根据一个实施例,可以追加包含药剂学上可接受的赋形剂。具体而言,所述赋形剂可以包括选自由乙基纤维素、羟丙基纤维素、羟丙基甲基纤维素、羧甲基纤维素钠、聚环氧乙烷、卡波姆、海藻酸钠、甘露醇、交联羧甲基纤维素钠、碳酸氢钠及硬脂酸镁构成的组的一种以上。
根据一个实施例,所述组合物可以以片剂、胶囊剂或混悬剂的形式提供。具体而言,可以为帕马考昔及普瑞巴林混合的片剂、胶囊或混悬剂形式,所述片剂可以包括双层片、多层片或单一片的形式。
另外,可以以帕马考昔、普瑞巴林或它们的混合物区分为各不相同层的状态的双层结构的双层片或多层结构的多层片形成。
根据一个实施例,可以以区分为缓释层及速释层的双层形成。具体而言,所述缓释层可以包含普瑞巴林,所述速释层可以包含帕马考昔。
根据一个实施例,可以还包含药剂学上可接受的包衣基料。
另外,可以进一步包含药剂学上可接受的载体。
其他本发明实施例的具体事项包括于以下详细说明中。
发明效果
根据本发明的包含帕马考昔及普瑞巴林的用于治疗疼痛的药剂学组合物,所述组合物的各个药物释放曲线与市销中含有普瑞巴林的经口剂型乐瑞卡胶囊及Acelex片剂类似。具体而言,通过将帕马考昔与普瑞巴林制成一个单一剂型,因而各个药物在剂型内的相互作用可以最小化,1日服用1次或2次,便可以互补地可持续地发挥各个药物效果。
本发明的组合物具有对外部物理因素的稳定性,颗粒流动性优秀,可以提高均一性,因而容易处置,可以提高生产率。
附图说明
图1是显示实验例1的帕马考昔比较溶出曲线的图表。
图2是显示实验例1的普瑞巴林比较溶出曲线的图表。
图3是显示实验例2的帕马考昔比较溶出曲线的图表。
图4是显示实验例2的普瑞巴林比较溶出曲线的图表。
图5是显示实验例3的帕马考昔比较溶出曲线的图表。
图6是显示实验例4的帕马考昔比较溶出曲线的图表。
图7及8是显示实验例5的比较溶出曲线的图表。
图9及10是显示实验例6的比较溶出曲线的图表。
图11是显示实验例7的比较溶出曲线的图表。
图12是显示实验例8的比较溶出曲线的图表。
图13是显示实验例9的比较溶出曲线的图表。
图14是显示实验例10的比较溶出曲线的图表。
图15是显示实验例11的比较溶出曲线的图表。
图16是显示实验例11及实验例12的普瑞巴林比较溶出曲线的图表。
图17是显示实验例12的帕马考昔比较溶出曲线的图表。
具体实施方式
本发明可以施加多样的变换,可以具有多种实施例,将在附图中示例性图示特定实施例并在下文中详细说明。但是,这并非要针对特定实施形式而限定本发明,应理解为包括本发明的思想及技术范围内包含的所有变换、均等物以及替代物。在说明本发明方面,当判断认为对相关公知技术的具体说明可能混淆本发明要旨时,省略该详细说明。
下面对本发明实施例的药剂学组合物进行更详细说明。
本说明书中使用的术语“药剂学组合物”可以与“药学组合物”及“药学上可接受的组合物”混用记载,作为可以对给药对象发挥较为非毒性、无害的有效作用的组合物,可以意味着因所述组合物引起的副作用不降低药物效能,不对化合物给药对象诱发严重刺激,不损伤化合物的生物学活性与物性的任意有机或无机化合物剂型。
本发明中使用的术语“给药对象”,可以与“给药个体”及“给药有机体”混用记载,可以意味着已诱发或可能诱发急性或慢性疼痛的包括人类在内的所有动物。
本发明提供一种包含帕马考昔及普瑞巴林的用于治疗疼痛的药剂学组合物。帕马考昔与普瑞巴林复合制剂与其他药剂学上可接受的添加剂混合时,可以表现出减小活性成分的变形、增加对时间变化的稳定性的效果。
根据一个实施例,所述组合物可以为液体或固体形状,可以以适合与水或其他适当液体介质一同配制的诸如包衣片、丸剂、颗粒、胶囊、悬浮液、乳剂或粉末形式的任意便利的形式提供。例如,所述组合物可以以片剂、胶囊剂、混悬剂等形式形成。例如,可以制备成帕马考昔及普瑞巴林混合的包衣片、片剂、胶囊或混悬剂形式,所述包衣片可以包括单层、双层或多层包衣片的形式,所述片剂可以包括双层片、多层片或单一片的形式。另外,例如可以形成为以微粒、颗粒、丸剂形式填充的胶囊剂型。
具体而言,例如,普瑞巴林由于原料特性上的原因,可以制备成在制备工序中受到外部物理因素影响小的胶囊剂型的形式。另外,可以以能够改善不稳定性的压片压力制备,制备成使相关物质的生成实现最小化的片剂形式。另外,由于普瑞巴林成分的体内吸收机理特性上的原因,在胃中长时间滞留,这会对药物吸收发挥有效作用,因而可以制备成胃滞留片剂的剂型。
另外,根据一个实施例,可以以帕马考昔、普瑞巴林或它们的混合物区分为各不相同层的状态的双层结构的双层片或多层结构的多层片形成。例如,可以以由缓释层及速释层结构构成的双层或多层形成,所述缓释层可以包含普瑞巴林,所述速释层可以包含帕马考昔。根据具体的实施例,可以在速释层以帕马考昔及普瑞巴林混合物颗粒形成层并压实后,在缓释层以普瑞巴林颗粒形成层,利用压片机制备。另外,例如可以在速释层形成含有帕马考昔层,在缓释层形成普瑞巴林层,利用压片机制备。
所述双层的制备方法,可以利用普瑞巴林及其混合物颗粒形成下层并压实后,以帕马考昔及其混合物颗粒形成上层,利用压片机制备,但并非限定于此。
根据一个实施例,可以以在内核的普瑞巴林层包含外核的帕马考昔层,或在内核的帕马考昔层包含外核的普瑞巴林层的有核剂型形成。另外,可以以在内层的普瑞巴林层包含外层的帕马考昔包衣或在内层的帕马考昔层包含外层的普瑞巴林层的双重释放微包衣剂型(DRM)形成。
根据一个实施例,帕马考昔相对普瑞巴林的比率例如可以为1至300:1至600重量比,例如可以为1:1至1:300重量比,例如可以为2:1至2:300。
另外,相对于组合物总重量,例如可以包含帕马考昔0.1至10重量%及普瑞巴林10至50重量%。例如相对于组合物总重量,可以包含帕马考昔0.3至1.0重量%及普瑞巴林10至30重量%。另外,例如在组合物内可以包含帕马考昔1至5mg,例如1至2mg,以及普瑞巴林75至300mg,例如75至150mg。
根据一个实施例,可以进一步包含药剂学上可接受的赋形剂(excipien t)。例如,作为赋形剂,可以包括选自由乙基纤维素(ethyl cellulose)、羟丙基纤维素(hydroxypropyl cellulose)、羟丙基甲基纤维素(hydroxypropylmethylcellulose)、羧甲基纤维素钠(sodium carboxymethyl cellulose)、聚环氧乙烷(polyethylene oxide)、卡波姆(carbomer)、海藻酸钠(sodium a lginate)、甘露醇(mannitol)、交联羧甲基纤维素钠(cross carmellose sodi um)、碳酸氢钠(sodium hydrogen carbonate)及硬脂酸镁(magnesium st earate)构成的组的一种以上。其中,例如可以包含选自由羟丙基甲基纤维素、D-甘露醇、羟丙基纤维素、交联羧甲基纤维素钠、碳酸氢钠、硬脂酸镁构成的组的一种以上。
具体而言,例如,为了在混合物状态的组合物内提高帕马考昔活性成分的混合均一性及压片性,可以使用作为颗粒均一的不溶性高分子的甘露醇200SD,但并非限定于此。
另外,具体而言,例如,当组合物是由缓释层及速释层构成的双层剂型时,作为缓释型基质赋形剂,可以包括选自由羟丙基甲基纤维素、聚环氧乙烷(PEO)、卡波姆、海藻酸钠、乙基纤维素、羟丙基纤维素及羧甲基纤维素钠等构成的组的一种以上,例如可以包括羟丙基甲基纤维素。另外,例如为了使药物可以在胃脏内漂浮既定时间并在胃内长时间停留,可以诱发在片剂表面产生气体而增加漂浮性,此时,可以使用包括碳酸氢钠的赋形剂。
根据一个实施例,考虑到影响胃肠蠕动及其他缓释型药物释放的因素,与所述赋形剂一同添加的缓释基质相对于缓释层全体重量,可以包含10至70%,例如30至50%。另外,提高片剂漂浮性的碳酸氢钠添加适量以上的含量时,反而会增加片剂的崩解,妨碍药物的释放,因而例如相对于组合物总重量,可以包含1至15%,例如8至12%。
根据一个实施例,所述组合物为了确保具有光敏特性的帕马考昔与稳定性受到水分、温度等外部因素影响的普瑞巴林的长期稳定性,可以包括包衣基料。作为包衣基料,例如可以使用水溶性包衣基料,可以使用通常使用的包衣基料。具体而言,例如可以包括包含聚乙烯醇衍生物、甲基丙烯酸衍生物及聚丙烯酸衍生物的包衣基料,例如可以利用选自由欧巴代 考丽卡特及羟丙基甲基纤维素(HPMC)构成的组的1种或2种以上,例如可以利用水分及光线阻断效果比较优秀的含聚乙烯醇欧巴代
根据一个实施例,可以追加包含药剂学上可接受的载体。作为载体,可以利用制剂时通常使用的载体,例如可以包含乳糖(lactose)、右旋糖(d extrose)、蔗糖(sucrose)、山梨糖醇(sorbitol)、甘露醇(mannitol)、淀粉(starch)、阿拉伯胶、磷酸钙(calciumphosphate)、藻朊酸盐(alginate)、明胶(gelatin)、硅酸钙(calcium silicate)、微晶纤维素、聚乙烯吡咯烷酮(polyvinyl pyrrolidone)、纤维素(cellulose)、水、糖浆(syrup)、甲基纤维素(methyl cellulose)、苯甲酸甲酯(methyl hydroxyl benzoate)、苯甲酸丙酯(propyl hydroxyl benzoate)、滑石(talc)、硬脂酸镁(magnesium ste arate)及矿物油(mineral oil)等,但并非限定于此。
根据一个实施例,除所述成分外,可以包含填充剂、增量剂、粘合剂、崩解剂、增溶剂、防腐剂、缓冲剂、助流剂、吸潮剂、包衣剂、着色剂、水溶性添加剂、润滑剂、润湿剂、甜味剂、香味剂、乳化剂、混悬剂和防腐剂等通常使用的药剂学上可接受的物质作为追加添加剂。这种添加剂可以在对本发明组合物有效成分影响最小的含量范围内包含,例如可以相对于组合物总重量包含5至90重量%,例如40至90重量%。
根据一个实施例,所述组合物可以作用于因炎症性或神经病症性而诱发的疼痛,例如急性疼痛、慢性疼痛。具体而言,例如可以作为用于治疗包括糖尿病性神经障碍在内的神经性疼痛(neurogenic pain)、因广泛性焦虑障碍(generalized anxiety disorder)导致的疼痛、纤维肌痛(fibromyalgi a)、痛觉过敏症(hyperalgesia)、异常痛觉(allodynia)、癌症疼痛(cancer pain)、骨关节炎(osteoarthritis)、类风湿性关节炎(rheumatoid arthritis)、强直性脊椎炎(ankylosing spondylitis)、五十肩(frozenshoulder)、腰痛(l umbodynia)或坐骨神经痛(sciatica)的镇痛剂而表现出有效效果。另外,例如可以用于对诸如类风湿性关节炎、强直性脊椎炎、坐骨神经痛及五十肩的炎症性因素的重度疼痛至中度疼痛的治疗用途。
本发明的药剂或药学组合物可以根据本领域技术人员已知的标准工序制备成适合应用于包括婴儿、儿童在内的人类和成年动物的任何形式。
下面对本发明的实施例进行详细说明,以便本发明所属技术领域的普通技术人员可以容易地实施。但是,本发明可以以多种不同的形式体现,这些实施例只用于对本发明进行举例,因而不得解释为本发明的范围由这些实施例所限定。
实施例1
通过与具有稳定性不足特性的普瑞巴林主成分进行配合适合性试验,选拔出无药物-赋形剂间相互作用的赋形剂,将其种类进行最少化。以帕马考昔与普瑞巴林为主成分,利用如表1所示的赋形剂,以湿式颗粒形式进行联合、干燥、成粒及混合,并填充胶囊。网使用30目(mesh)。
[表1]
实验例1
根据韩国药典溶出试验法的第二种方法(桨法,装置2)规格,进行了实施例1制剂的体外(in vitro)比较溶出试验。使用现在市销品作为对照药,具体而言,对于帕马考昔,使用现在本公司制品Acelex胶囊作为对照药进行了比较溶出试验,对于普瑞巴林,将乐瑞卡胶囊制品作为对照药进行了比较溶出试验。
作为对帕马考昔成分的溶出试验液,使用实施例1与对照药的溶出差异最大的溶出液,即pH 1.2的韩国药典第11版崩解试验法的第一种液体,试验温度为37±0.5℃,旋转速度为50rpm,其结果显示于表2及图1中。
另外,作为对普瑞巴林成分的溶出试验液,在pH 1.2的韩国药典第11版崩解试验法的第一种液体、pH 4.0的日本药典第17版0.05mol/L乙酸·乙酸钠缓冲液、pH 4.0、pH6.8的韩国药典第11版崩解试验法的第二种液体或水的4种溶出液中均呈现出类似的曲线,因而以作为起始溶出液的0.06N HCL进行了试验,其将结果显示于表3及图2。
溶出率表示为平均值,单位为%。
[表2]
区分 | 时间(分钟) | 0 | 5 | 10 | 15 | 30 | 45 | 60 |
实施例1 | 平均 | 0 | 67.0 | 85.7 | 87.9 | 90.2 | 92.5 | 94.0 |
对照药(Acelex胶囊) | 平均 | 0 | 37.2 | 56.8 | 72.4 | 84.3 | 88.5 | 91.7 |
[表3]
区分 | 时间(分钟) | 0 | 5 | 10 | 15 | 30 | 45 | 60 |
实施例1 | 平均 | 0 | 60.2 | 96.8 | 99.3 | 100.3 | 100.8 | 101.2 |
对照药(乐瑞卡胶囊) | 平均 | 0 | 61.7 | 96.0 | 98.9 | 100.6 | 100.2 | 100.7 |
如表及附图所示,实施例1组合物与对照药的初始溶出率出现差异。
实施例2
如表4所示调节崩解剂,以与实施例1相同的方法填充胶囊。
[表4]
实验例2
针对实施例2制剂,以与实验例1相同的方法进行了比较溶出试验。
对帕马考昔的试验液为pH 1.2,结果显示于表5及图3,对普瑞巴林的试验液为pH0.06N HCL,显示于表6及图4中。
[表5]
区分 | 时间(分钟) | 0 | 5 | 10 | 15 | 30 |
实施例2 | 平均 | 0 | 64.9 | 94.5 | 98.0 | 101.5 |
对照药(Acelex胶囊) | 平均 | 0 | 41.4 | 64.9 | 77.5 | 92.7 |
[表6]
区分 | 时间(分钟) | 0 | 5 | 10 | 15 | 30 | 45 | 60 |
实施例2 | 平均 | 0 | 34.9 | 85.4 | 91.1 | 94.8 | 95.2 | 95.4 |
对照药(乐瑞卡胶囊) | 平均 | 0 | 72.7 | 96.7 | 98.3 | 98.6 | 99.3 | 99.6 |
如表及附图所示,借助于崩解剂,普瑞巴林与对照药的溶出差异增加。
实施例3
以表7的组成,除利用16或20目(mesh)的网进行处理之外,以与实施例1相同的方法填充胶囊。
[表7]
实验例3
为了确认制备工序中网(mesh)的变化和有无崩解剂导致的溶出变化,针对实施例3的帕马考昔,以与实验例1相同的方法进行了比较溶出试验。溶出液使用pH 1.2,对照药使用Acelex胶囊,其结果显示于表8及图5中。
[表8]
实施例4
根据表9的组成,除制备成片剂形式外,以与实施例3相同的方法制备。制备片剂时,考虑到普瑞巴林的不稳定性,选定最佳压片压力进行。
[表9]
实验例4
将实施例4制剂按不同硬度制备成片剂,针对帕马考昔成分,以与实验例1相同的方法进行比较溶出试验。
作为溶出试验液,使用pH 1.2的韩国药典第11版崩解试验法的第一种液体或pH4.0的日本药典第17版0.05mol/L乙酸·乙酸钠缓冲液,对照药使用Acelex片剂。比较溶出试验结果显示于表10及图6中。
[表10]
实验例5
根据实施例4组成,按不同硬度制备片剂后,针对普瑞巴林成分,在pH 1.2的韩国药典第11版崩解试验法的第一种液体、pH 4.0的日本药典第17版0.05mol/L乙酸·乙酸钠缓冲液、pH 4.0、pH 6.8的韩国药典第11版崩解试验法的第二种液体或水中,以与实验例1相同的方法进行比较溶出试验。对照药使用乐瑞卡胶囊。结果显示于表11、表12、图7及图8中。
[表11]
[表12]
实施例5
增加实施例4制剂的制备单位时,除为了提高生产设施中片剂的压片性而按表13的组成进行外,以与实施例4相同的方法制备了片剂。含有结晶型普瑞巴林组合物在压片时可能发生顶裂(capping)现象,因而为了改善这种情况,添加具有微粉粒度的微晶纤维素而增加赋形剂的量,将原来在后混合中添加的交联羧甲基纤维素钠添加于颗粒。
[表13]
实施例6
除为了从实施例5制剂进一步改善压片性而按表14的组成进行外,以与实施例4相同的方法制备了片剂。具体而言,增加赋形剂含量,添加二氧化硅。
[表14]
实验例6
针对实施例6制剂,以与实验例1相同的方法进行了比较溶出试验。溶出试验液使用pH 1.2或水,帕马考昔的对照药使用Acelex片剂,普瑞巴林的对照药使用乐瑞卡胶囊。
对帕马考昔成分的比较溶出试验结果显示于表15及图9中,对普瑞巴林成分的比较溶出试验结果显示于表16及图10中。
[表15]
[表16]
实施例7
根据表17制备了含有表现出缓释性的普瑞巴林层与表现出速释性的普瑞巴林、帕马考昔层的双层复合片剂。在作为上层的速释层,添加主成分帕马考昔与相当于普瑞巴林一半的量,制备了组合物,以便表现出速释性药物释放,在作为下层的缓释层,将相当于普瑞巴林剩余一半的量,添加缓释性基料,制备了双层复合制剂。缓释性基料使用羟丙基甲基纤维素、卡波姆及PEO。
[表17]
实施例8
除按表18的组成进行外,以与实施例7相同的方法制备了复合片剂。缓释性基料使用羟丙基甲基纤维素、海藻酸钠及羧甲基纤维素钠。
[表18]
实验例7
以与实验例1相同的方法,进行了实施例7及8的片剂溶出试验,其结果显示于表19及图11中。
[表19]
实验例8
以与实验例1相同的方法,进行了实施例7及8的溶出试验,为了测量胃肠道蠕动抵抗性,将溶出桨速度从50rpm增加到100rpm,进行了溶出试验。
其结果显示于表20及图12。
[表20]
如表所示,旋转速度变更导致的溶出率变化,表现为4至8%以内结果,因而估计因胃肠道蠕动导致发生急剧的药物释放现象的可能性低。
实验例9
只以实施例7及8的组成中的缓释层部分的组成制备片剂,以与实验例1相同的方法进行了溶出试验。双层片剂的整体普瑞巴林溶出结果呈现迟效性(Controlled-release,CR)释放形式而非缓释(sustain-release,SR)形式,为了确认作为下层部分的缓释层部分的溶出形式而进行了溶出试验。结果显示于表21及图13中。
[表21]
实施例9及10
将双层复合制剂组合物中的普瑞巴林添加于缓释层部分,而不是分为上、下层的速释层、缓释层,以如表22所示的组成制备了片剂。作为缓释性基料的海藻酸钠在进行稳定性试验时,会对因吸潮而发生组合物性状变化产生影响,因而缓释基质使用羟丙基甲基纤维素、卡波姆及PEO。
[表22]
实验例10
针对实施例9及10的片剂,以与实验例1相同的方法进行了溶出试验。结果显示于表23及图14。
[表23]
实施例11
以实验例10的结果为基础,选定了最佳组合物。为了制备不影响溶出率而用于减小片剂大小的组合物,根据表24的组成制备了片剂。如表的组成所示,在减小速释层的量的同时,减小缓释层含有的赋形剂的量,从而减小最终片剂的重量。另外,为了改善普瑞巴林主成分因施加的压片压力导致的不稳定性,按不同片剂硬度制备了制剂。具体而言,分别制备了5kp及9kp硬度的片剂。
[表24]
实验例11
普瑞巴林主成分具有压片压力导致的不稳定性,因而将实施例11制剂按不同硬度制备片剂,进行了溶出试验。结果显示于表25及图15中。
[表25]
如表所示,片剂不同硬度的溶出结果可以确认,基于压片压力的溶出率没有有效程度的差异。另外,如果考查实验例10及11的结果,可以确认为了减小片剂大小而减少赋形剂,不会给溶出率带来大的差异。
实施例12
提高制备规模,在生产设施中制备片剂时,含有帕马考昔的上层组合物的含量低,制备后,为了改善片剂的质量偏差及含量不均一的问题,使上层的质量增加适当量,以如表26所示的组成制备了片剂。
[表26]
实验例12
针对实施例11及实施例12片剂,以与实验例1相同的方法进行了溶出试验。对普瑞巴林成分的比较溶出试验结果显示于表27及图16中,对帕马考昔成分的比较溶出试验结果显示于表28及图17中。
[表27]
[表28]
如上所述可以确认,本发明的组合物的药物释放曲线与市销的含普瑞巴林的经口剂型乐瑞卡胶囊及Acelex片剂类似。在将帕马考昔和普瑞巴林制剂成一个单一剂型方面,可知在单一剂型内没有两种药物的相互作用,确认了可以设计成服用次数1日1次或2次便可以互补性地可持续发挥各个药物效果。另外,普瑞巴林由于诸如压片压力的外部物理因素导致相关物质增加,具有稳定性可能发生问题的特性,因而为了完善这种情况而应用了适当压片压力,与胶囊剂型相比,确认了片剂形式在制剂生产时,在稳定性方面会更优秀。另外,就胶囊剂型而言,确认了颗粒流动性优秀,填充时无质量偏差,均一度比较优秀。另外,除单一复合速释片之外,确认了可以减小服用次数的具有普瑞巴林缓释片和帕马考昔速释片双层剂型的复合制剂的可能性。
以上说明只不过示例性地说明了本发明的技术思想,只要是本发明所属技术领域的技术人员,便可以在不超出本发明本质性特性的范围内多样地修订及变形。另外,本发明中公开的实施例并非用于限定而是用于说明本发明的技术思想,并非本发明的技术思想范围由这种实施例所限定。本发明的保护范围应根据以下权利要求书进行解释,处于与之同等范围内的所有技术思想应解释为包含于本发明的权利范围。
Claims (16)
1.一种药剂学组合物,用于治疗疼痛,其中,
包含帕马考昔及普瑞巴林。
2.根据权利要求1所述的药剂学组合物,其中,
所述组合物用于因炎症性或神经病症性而诱发的急性或慢性疼痛治疗。
3.根据权利要求1所述的药剂学组合物,其中,
所述组合物将包括糖尿病性神经障碍的神经源性疼痛、因广泛性焦虑障碍导致的疼痛、纤维肌痛、痛觉过敏症、异常痛觉、癌症疼痛、骨关节炎、类风湿性关节炎、脊椎炎、五十肩、腰痛或坐骨神经痛作为适应症。
4.根据权利要求1所述的药剂学组合物,其中,
帕马考昔相对普瑞巴林的比率为1至300:1至600重量比。
5.根据权利要求1所述的药剂学组合物,其中,
帕马考昔相对普瑞巴林的比率为1:1至1:300重量比。
6.根据权利要求1所述的药剂学组合物,其中,
帕马考昔相对普瑞巴林的比率为2:1至2:300重量比。
7.根据权利要求1所述的药剂学组合物,其中,
相对于组合物总重量,包含帕马考昔0.1至10重量%及普瑞巴林10至50重量%。
8.根据权利要求1所述的药剂学组合物,其中,
进一步包含药剂学上可接受的赋形剂。
9.根据权利要求8所述的药剂学组合物,其中,
所述赋形剂包括选自由乙基纤维素、羟丙基纤维素、羟丙基甲基纤维素、羧甲基纤维素钠、聚环氧乙烷、卡波姆、海藻酸钠、甘露醇、交联羧甲基纤维素钠、碳酸氢钠及硬脂酸镁构成的组的一种以上。
10.根据权利要求1所述的药剂学组合物,其中,
为片剂、胶囊剂或混悬剂的形式。
11.根据权利要求11所述的药剂学组合物,其中,
为帕马考昔及普瑞巴林混合的片剂、胶囊或混悬剂形式,所述片剂包括双层片、多层片或单一片的形式。
12.根据权利要求1所述的药剂学组合物,其中,
以帕马考昔、普瑞巴林或它们的混合物区分为各不相同层的状态的双层结构的双层片或多层结构的多层片形成。
13.根据权利要求1所述的药剂学组合物,其中,
以区分为缓释层及速释层的双层形成。
14.根据权利要求13所述的药剂学组合物,其中,
所述缓释层包含普瑞巴林,所述速释层包含帕马考昔。
15.根据权利要求1所述的药剂学组合物,其中,
还包含药剂学上可接受的包衣基料。
16.根据权利要求1所述的药剂学组合物,其中,
进一步包含药剂学上可接受的载体。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0037054 | 2018-03-30 | ||
KR1020180037054A KR102631399B1 (ko) | 2018-03-30 | 2018-03-30 | 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물 |
PCT/KR2019/003225 WO2019190118A1 (ko) | 2018-03-30 | 2019-03-20 | 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111867578A true CN111867578A (zh) | 2020-10-30 |
Family
ID=68062241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980020180.0A Pending CN111867578A (zh) | 2018-03-30 | 2019-03-20 | 包含帕马考昔及普瑞巴林的用于治疗疼痛的药剂学组合物 |
Country Status (8)
Country | Link |
---|---|
US (2) | US11602517B2 (zh) |
EP (1) | EP3777849A4 (zh) |
JP (1) | JP2021517115A (zh) |
KR (1) | KR102631399B1 (zh) |
CN (1) | CN111867578A (zh) |
BR (1) | BR112020017773A2 (zh) |
CA (1) | CA3093899A1 (zh) |
WO (1) | WO2019190118A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022097764A1 (ko) * | 2020-11-04 | 2022-05-12 | 전남대학교병원 | 프레가발린 및 티아넵틴을 포함하는 신경병성 통증 치료용 약학적 조성물 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024068242A1 (en) * | 2022-09-29 | 2024-04-04 | Triviumvet Designated Activity Company | Veterinary compositions for use in the treatment of neuropathic pain |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6593368B2 (en) * | 1997-09-08 | 2003-07-15 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
US20160008371A1 (en) * | 2014-07-14 | 2016-01-14 | Autotelic Llc | Fixed dose combination for pain relief without edema |
US20160120885A1 (en) * | 2014-07-14 | 2016-05-05 | Autotelic Llc | Fixed dose combination for pain relief without edema |
WO2018015946A1 (en) * | 2016-07-17 | 2018-01-25 | Mapi Pharma Ltd. | Extended release dosage forms of pregabalin |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ513924A (en) | 1999-03-01 | 2001-09-28 | Ortho Mcneil Pharm Inc | Composition comprising a tramadol material and a selective cox-2 inhibitor drug |
KR100495389B1 (ko) | 1999-04-14 | 2005-06-16 | 주식회사 태평양 | 시클로옥시게네이즈-2 저해제로서의4,5-디아릴-3(2h)-퓨라논 유도체 |
DE19927688A1 (de) | 1999-06-17 | 2000-12-21 | Gruenenthal Gmbh | Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac |
RU2286151C2 (ru) | 2002-02-22 | 2006-10-27 | Уорнер-Ламберт Компани Ллс | Комбинации альфа-2-дельта-лиганда с селективным ингибитором циклооксигеназы-2 |
CA2497780A1 (en) * | 2002-10-17 | 2004-04-29 | Novartis Ag | Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors |
CA2574627A1 (en) * | 2004-07-22 | 2006-02-02 | Pharmacia Corporation | Compositions for treatment of inflammation and pain using a combination of a cox-2 selective inhibitor and a ltb4 receptor antagonist |
EP1917000A2 (en) | 2005-07-07 | 2008-05-07 | Farnam Companies, Inc. | Sustained release pharmaceutical compositions for highly water soluble drugs |
JP5537441B2 (ja) | 2008-03-04 | 2014-07-02 | ファイザー・リミテッド | 慢性疼痛を治療する方法 |
EP2311446A1 (en) | 2009-10-16 | 2011-04-20 | Laboratorios Del. Dr. Esteve, S.A. | Compositions comprising Tramadol and Celecoxib in the treatment of pain |
MX2014002163A (es) | 2011-08-26 | 2014-09-25 | Wockhardt Ltd | Métodos para el tratamiento de desórdenes cardiovasculares. |
KR20130078147A (ko) | 2011-12-30 | 2013-07-10 | 한미약품 주식회사 | 일정한 입도를 갖는 4,5―디아릴―3(2h)―퓨라논 유도체를 포함하는 약학 조성물 |
KR101446601B1 (ko) * | 2014-01-29 | 2014-10-07 | 크리스탈지노믹스(주) | 5-(4-(아미노설포닐)페닐)-2,2-디메틸-4-(3-플루오로페닐)-3(2h)-퓨라논을 포함하는 약학적 조성물 및 캡슐 제형 |
WO2016192680A1 (en) | 2015-06-03 | 2016-12-08 | Triastek, Inc. | Dosage forms and use thereof |
KR101710792B1 (ko) | 2015-07-14 | 2017-02-28 | 주식회사 유영제약 | 세레콕시브 및 트라마돌을 함유하는 약제학적 조성물 |
KR20170135163A (ko) | 2016-05-30 | 2017-12-08 | 크리스탈지노믹스(주) | 폴마콕시브를 포함하는 관절 내 국소 투여용 제어방출성 마이크로입자 제제 |
-
2018
- 2018-03-30 KR KR1020180037054A patent/KR102631399B1/ko active IP Right Grant
-
2019
- 2019-03-20 WO PCT/KR2019/003225 patent/WO2019190118A1/ko unknown
- 2019-03-20 CA CA3093899A patent/CA3093899A1/en active Pending
- 2019-03-20 EP EP19777560.4A patent/EP3777849A4/en active Pending
- 2019-03-20 JP JP2020545470A patent/JP2021517115A/ja active Pending
- 2019-03-20 US US16/982,137 patent/US11602517B2/en active Active
- 2019-03-20 CN CN201980020180.0A patent/CN111867578A/zh active Pending
- 2019-03-20 BR BR112020017773-3A patent/BR112020017773A2/pt unknown
-
2023
- 2023-01-17 US US18/155,240 patent/US20230293476A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6593368B2 (en) * | 1997-09-08 | 2003-07-15 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
US20160008371A1 (en) * | 2014-07-14 | 2016-01-14 | Autotelic Llc | Fixed dose combination for pain relief without edema |
US20160120885A1 (en) * | 2014-07-14 | 2016-05-05 | Autotelic Llc | Fixed dose combination for pain relief without edema |
WO2018015946A1 (en) * | 2016-07-17 | 2018-01-25 | Mapi Pharma Ltd. | Extended release dosage forms of pregabalin |
Non-Patent Citations (2)
Title |
---|
MYUNGCHUL LEE等: "A Randomized, Multicenter, Phase III Trial to Evaluate the Efficacy and Safety of Polmacoxib Compared with Celecoxib and Placebo for Patients with Osteoarthritis", 《CLINICS IN ORTHOPEDIC SURGERY》 * |
SARAPEE HIRANKARN等: "GCG100649, A Novel Cyclooxygenase‐2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase‐I/II: Preliminary Dose–Exposure Relationships to Define Clinical Development Strategies", 《CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022097764A1 (ko) * | 2020-11-04 | 2022-05-12 | 전남대학교병원 | 프레가발린 및 티아넵틴을 포함하는 신경병성 통증 치료용 약학적 조성물 |
Also Published As
Publication number | Publication date |
---|---|
CA3093899A1 (en) | 2019-10-03 |
US20210113515A1 (en) | 2021-04-22 |
EP3777849A1 (en) | 2021-02-17 |
US11602517B2 (en) | 2023-03-14 |
WO2019190118A1 (ko) | 2019-10-03 |
BR112020017773A2 (pt) | 2020-12-22 |
KR102631399B1 (ko) | 2024-02-01 |
KR20190114403A (ko) | 2019-10-10 |
EP3777849A4 (en) | 2022-02-23 |
US20230293476A1 (en) | 2023-09-21 |
JP2021517115A (ja) | 2021-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170216212A1 (en) | Tapentadol compositions | |
EP2217217B1 (en) | Controlled release pharmaceutical compositions of pregabalin | |
EP2575798B1 (en) | Gastroretentive dosage forms of gaba analogs | |
US6558701B2 (en) | Multilayer tablet for administering a fixed combination of tramadol and diclofenac | |
US20130280324A1 (en) | Sustained release pharmaceutical compositions comprising pregabalin | |
EP1849462B1 (en) | A method of alleviating signs and symptons of Spasticity | |
US20230078925A1 (en) | Pulsatile drug delivery system for treating morning akinesia | |
US20230293476A1 (en) | Pharmaceutical composition, comprising polmacoxib and pregabalin, for treatment of pain | |
US8968778B2 (en) | Threo-DOPS controlled release formulation | |
WO2016187718A1 (en) | Controlled extended release pregabalin | |
JP2019507101A (ja) | 含プレガバリン経口用徐放性三重錠剤 | |
RU2789402C1 (ru) | Фармацевтическая композиция, содержащая полмакоксиб и прегабалин, для лечения боли | |
US8158149B2 (en) | Threo-DOPS controlled release formulation | |
KR102039345B1 (ko) | 프레가발린 함유 고팽윤성 서방성 삼중정제 | |
US20140112995A1 (en) | Multi-layered, multiple unit pharmaceutical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |